Pfizer Inc. remains attractive with strong fundamentals, cost control, an expanding market, and new drugs. Click here to read ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Pfizer (PFE), which belongs to the Zacks Large ...

Pfizer (PFE) closed at $27.37 in the latest trading session, marking a +1.07% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.01%. Elsewhere, the Dow saw an ...

Currently, Pfizer's stock carries a consensus rating of "Hold," with an average target price of $28.12, indicating mixed sentiments among analysts. Recent upgrades and downgrades illustrate the ...

In exchange, Pfizer will receive a three-year exemption from tariffs on pharmaceutical imports if it increases U.S.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $29.25, a high estimate of $33.00, and a low estimate of $26.00. Marking an ...

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Detailed price information for Stanley Black & Decker Inc (SWK-N) from The Globe and Mail including charting and trades.

As the financial landscape continues to evolve, investors are keenly monitoring key market players and economic indicators. In this article, we delve into the latest updates from the Zacks Analyst ...

Pfizer PFE announced a definitive agreement to acquire obesity drug developer, Metsera MTSR, to re-enter the lucrative obesity space after it scrapped the development of danuglipron, a weight-loss ...

Pfizer acquires Metsera to enter the booming obesity drug market with next-gen GLP-1 therapies. Find out why PFE stock is a ...